Immunovant (IMVT) CFO awarded RSUs and 94,002 options under 2019 plan

Rhea-AI Filing Summary

Immunovant, Inc. Chief Financial Officer Tiago Girao received new equity awards as part of his compensation. He was granted stock options for 94,002 shares of common stock at an exercise price of $24.61 per share, expiring in 2036, and 64,968 restricted stock units that convert into common shares as they vest.

The RSUs vest 25% on April 1, 2027, with the remainder in 12 quarterly installments, while the options vest 25% on April 1, 2027 and the balance in 36 monthly installments, all contingent on continued service. Following the grant, he holds 273,356 common shares directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Girao Tiago

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	94,002	$0.00	--
Grant/Award	Common Stock	64,968	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 94,002 shares (Direct); Common Stock — 273,356 shares (Direct)

Footnotes (1)

1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Key Figures

RSUs granted: 64,968 units Stock options granted: 94,002 options Option exercise price: $24.61 per share +3 more

6 metrics

RSUs granted 64,968 units Restricted stock units granted to CFO on April 7, 2026

Stock options granted 94,002 options Options over common stock granted on April 7, 2026

Option exercise price $24.61 per share Exercise price for 94,002 stock options

Common shares after grant 273,356 shares Direct common stock holdings following RSU grant

RSU initial vesting date April 1, 2027 25% of RSUs vest on this date

Option expiration date April 7, 2036 Expiration of the granted stock options

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, vest, stock options, +1 more

5 terms

restricted stock units ("RSUs") financial

"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan")"

vest financial

"The RSUs will vest as to 25% of the total shares on April 1, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

stock options financial

"These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"conversion_or_exercise_price": "24.6100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Girao Tiago

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/07/2026		A		64,968(1)	A	$0	273,356	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.61	04/07/2026		A		94,002		(2)	04/07/2036	Common Stock	94,002	$0	94,002	D

Explanation of Responses:

1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

2. These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Remarks:

	/s/ Tiago Girao	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Immunovant (IMVT) report for Tiago Girao?

Immunovant reported that CFO Tiago Girao received new equity awards, not open-market trades. He was granted 64,968 restricted stock units and options for 94,002 shares, both tied to future vesting schedules and continued employment with the company.

How many Immunovant (IMVT) RSUs were granted to the CFO and how do they vest?

The CFO received 64,968 restricted stock units. Twenty-five percent vest on April 1, 2027, with the remaining 75% vesting in twelve substantially equal quarterly installments thereafter, so long as he continues providing service to Immunovant through each vesting date.

What are the terms of the Immunovant (IMVT) stock options granted to the CFO?

The CFO was granted options over 94,002 shares of common stock at a $24.61 exercise price. Twenty-five percent vest on April 1, 2027, with the remainder vesting in thirty-six substantially equal monthly installments, subject to his continued service, and the options expire in 2036.

How many Immunovant (IMVT) common shares does the CFO hold after these grants?

After the reported transactions, CFO Tiago Girao directly holds 273,356 shares of Immunovant common stock. This figure reflects his updated equity position following the award of 64,968 restricted stock units granted under the company’s 2019 Equity Incentive Plan.

Were Tiago Girao’s Immunovant (IMVT) awards part of a specific plan?

Yes. Both the restricted stock units and stock options were granted under Immunovant’s 2019 Equity Incentive Plan. The plan governs the terms of equity-based compensation, including vesting schedules and the requirement for continued service to receive the underlying common shares.

Do the reported Immunovant (IMVT) Form 4 transactions involve open-market buying or selling?

No. The transactions reflect compensation-related equity grants to the CFO, coded as awards, not open-market purchases or sales. They include new RSUs and stock options that will settle or become exercisable over time as vesting conditions are satisfied.